Dr. Steven Treon, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Dana-farber Cancer Institute

  Fellowship Hospital

• Massachusetts General Hospital

  Fellowship Hospital

• Boston Medical Center

  Residency Hospital, 1995

• Boston University Chobanian & Avedisian School Of Medicine

  Medical School, 1993

• Boston Medical Center

  Internship Hospital, 1993

• Genomic Evolution of Ibrutinib Resistant Clones in Waldenstrom Macroglobulinemia, 2020-02-27

• A pilot study on dasatinib in patients with Waldenstrom macroglobulinemia progressing on ibrutinib, 2022-06-07

• Molecular and cellular effects of NEDD8 activating enzyme (NAE) inhibition in myeloma, 2012-01-12

• Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia, 2021-09-16

• SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas, 2020-01-31

• NCCN Guidelines®Insights Multiple Myeloma, Version 3.2016 Featured Updates to the NCCN Guidelines, 2018-06-16

• Bone marrow involvement and subclonal diversity impairs detection of mutatedCXCR4by diagnostic next generation sequencing in Waldenstrom macroglobulinemia, 2021-03-13

• Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenstrom Macroglobulinemia., 2018-09-11

• Genomic landscape of Waldenstrom's macroglobulinemia, 2019-06-30

• A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader, 2017-11-09

• Partial response or better at 6 months is prognostic of superior progression-free survival in Waldenstrom macroglobulinemia patients treated with ibrutinib, 2020-11-18

• Immunogenicity of recurrent mutations in MYD88 and EZH2 in non-Hodgkin lymphomas, 2015-11-04